An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment.
Phase of Trial: Phase IV
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Fenofibrate (Primary) ; Pioglitazone (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 31 Jul 2017 Status changed from recruiting to completed.
- 21 Jul 2011 New trial record